ZFGN Zafgen, Inc.

4.90
+0  (0%)
Previous Close 4.90
Open 4.95
Price To book 1.10
Market Cap 134.02M
Shares 27,350,000
Volume 120,680
Short Ratio 3.62
Av. Daily Volume 173,248

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data due early 2Q 2017. Mid-May noted as latest possible date. Phase 2 trial to be initiated 2H 2017.
ZGN-1061
Obesity
Announced July 2016 suspension of development of Beloranib
Beloranib
Severe obesity
Announced July 2016 suspension of development of Beloranib
Beloranib
Prader-Willi Syndrome (PWS)
Announced July 2016 suspension of development of Beloranib
Beloranib
Severe obesity